Saso Cemerski
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Discovery of MK-2118, a Small-Molecule Agonist of STING.
Journal: ACS medicinal chemistry letters
Published: September 11, 2025
An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2025
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Journal: Journal of medicinal chemistry
Published: March 25, 2022
Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.
Journal: Scientific reports
Published: June 11, 2021
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Journal: Molecular cancer therapeutics
Published: February 11, 2021
Frontiers in cancer immunotherapy-a symposium report.
Journal: Annals of the New York Academy of Sciences
Published: October 16, 2020
An orally available non-nucleotide STING agonist with antitumor activity.
Journal: Science (New York, N.Y.)
Published: December 17, 2019
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 14, 2019
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Journal: Blood
Published: January 17, 2012
Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Journal: Immunology letters
Published: November 18, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026